Valsartan Capsules

This product is an angiotensin II receptor antagonist. This product can selectively act on the AT1 receptor subtype known to be related to the action of angiotensin II, selectively block the binding of angiotensin II to the AT1 receptor of tissue cells such as the adrenal glands and vascular smooth muscle, inhibit vasoconstriction and aldosterone secretion, and produce a hypotensive effect. The affinity of this product for AT1 receptors is about 20,000 times higher than that for AT2 receptors. This product does not affect the action of bradykinin and ion channel function, nor does it bind to the receptors of other hormones that play an important regulatory role in cardiovascular function. This product has no carcinogenic, teratogenic, mutagenic toxicity, and no reproductive toxicity.

The main ingredient of this product is valsartan, and its chemical name is: (S)-N-valeryl-N-{[2'-(1H-tetrazolyl-5-yl)[1,1'-biphenyl]-4-yl]methyl}-valine. Molecular formula: C24H29N5O3. Molecular weight: 435.53

This product is a hard capsule, and the contents are white powder.

Valsartan is suitable for all types of mild to moderate hypertension, especially for patients who are intolerant to ACE inhibitors.

The recommended dose is 80 mg (1 tablet), once a day, regardless of gender, age and race. The antihypertensive effect appears within 2 weeks, and the maximum effect is reached after 4 weeks. For patients whose blood pressure is not adequately controlled, the daily dose can be increased to 160 mg (2 tablets) or a diuretic can be added. This drug can be used in combination with other antihypertensive preparations. No dose adjustment is required for patients with mild to moderate renal impairment or non-biliary and non-cholestatic liver dysfunction. When hypertensive patients take this drug, their heart rate will not be affected while their blood pressure drops. When the drug is suddenly discontinued, there will be no blood pressure rebound and other clinical adverse reactions. Multiple doses of this drug have no significant effect on total cholesterol, fasting triglycerides, fasting blood glucose and uric acid.

Adverse reactions are rare, mild and transient: 1. Mild headache, dizziness, fatigue, abdominal pain, dry cough, and postural blood pressure changes are rare. 2. Increased blood potassium, decreased neutrophils, decreased hemoglobin and hematocrit, increased blood creatinine and transaminase are occasionally seen. 3. There are reports of adverse reactions such as diarrhea, rhinitis, pharyngitis, joint pain, and nausea.

It is contraindicated for those who are known to be allergic to this product; it is contraindicated for pregnant and lactating women.

Precautions for children: There are no studies on the effectiveness and safety of this product for children and adolescents (under 18 years old). Precautions for pregnancy and lactation: Pregnancy: Given the mechanism of action of angiotensin II antagonists, harm to the fetus cannot be ruled out. There have been reports that intrauterine administration of angiotensin-converting enzyme inhibitors (a specific class of drugs that act on RAAS) during the second and third trimesters of pregnancy can cause damage to the developing fetus or lead to fetal death. In addition, retrospective data show that the use of angiotensin-converting enzyme inhibitors in the first trimester of pregnancy has a potential risk of congenital defects. There have been reports of spontaneous abortion, oligohydramnios, and neonatal renal insufficiency when pregnant women inadvertently take valsartan. Similar to other drugs that directly act on RAAS, pregnant women should not use this product (see contraindications). For women who may become pregnant, doctors should inform them of the potential risks of this type of drug during pregnancy when prescribing drugs that act on RAAS. If pregnancy is discovered during medication, valsartan should be discontinued as soon as possible. Lactation: It is not clear whether valsartan is excreted in human milk. Valsartan is excreted in the milk of lactating rats. Therefore, this product should not be used during lactation. Precautions for the elderly: Although the systemic exposure concentration of valsartan in the elderly is slightly higher than that in young people, it has no clinical significance.

There is no significant interaction between this product and amlodipine, atenolol, cimetidine, digoxin, furosemide, glibenclamide, hydrochlorothiazide, and indomethacin. The antihypertensive effect of this product combined with atenolol is higher than that of either alone, but it cannot further reduce the heart rate compared with atenolol alone. The pharmacokinetics of this product are not changed when it is used in combination with warfarin, and the anticoagulant effect of warfarin is not affected by this product. When used in combination with potassium-sparing diuretics, potassium preparations, or potassium-containing salt substitutes, it can increase blood potassium.

Keep tightly closed.

80mg

36 months.

Bright Future Pharmaceutical(Hainan) Co., Ltd.

• Founded in:

  1992-10-12

• Address:

  No. 2, Yaogu 1st Road, Yaogu Industrial Park, Haikou National High-tech Industrial Development Zone

• Tax NO.:

  914600009840920311

• Registered Funds:

  60 million yuan

• Website:

  Log in to view

• Email:

  Log in to view